Folotyn for Non-Hodgkin's Lymphoma Baldwinsville NY

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Local Companies

Seung Shin Hahn
(315) 464-5276
750 E Adams St
Syracuse, NY
BENJAMIN HIMPLER, MD
(315) 472-7504
5008 Brittonfield Parkway
East Syracuse, NY
BERNARD POIESZ, MD
(315) 464-8200
750 E Adams Street
Syracuse, NY
Alicia Kay Bair, MD
315-472-4584
2200 E Genesee St Ste A
Syracuse, NY
Jeffrey Jay Kirshner, MD
315-472-7504
PO Box 2010
East Syracuse, NY
Ajeet Gajra
(315) 464-8200
750 E Adams St
Syracuse, NY
ANTHONY SCALZO, MD
(315) 472-7504
5008 Brittonfield Parkway
East Syracuse, NY
ALICIA BAIR, MD
(315) 464-8200
750 E Adams Street
Syracuse, NY
Mark David Adelson, MD
315-423-4222
1200 E Genesee St Ste 205
Syracuse, NY
Ajeet Gajra, MD
315-425-3456
800 Irving Ave (111)
Syracuse, NY
Data Provided by:
    

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles